November 14, 2013
Abbott’s m2000 menu is rapidly expanding as it recently added another U.S. Food and Drug Administration (FDA)-cleared test for the detection of toxigenic Clostridium difficile (C. difficile), a common and serious bacterial infection. The new test, developed and manufactured by IntelligentMDx (IMDx) of Waltham, Mass., offers an accurate way to aid in the diagnosis of C. difficile-associated disease and to facilitate hospital infection control.
September 16, 2013
Sept. 16, 2013 – With another flu season approaching, Abbott announced it will add a new U.S. Food and Drug Administration-cleared molecular diagnostic test for detection and differentiation of influenza A and influenza B and respiratory syncytial virus (RSV) to their broad infectious disease testing menu. The IMDx Flu A/B and RSV test developed by IntelligentMDx (IMDX) of Cambridge, Massachusetts, is performed on Abbott's m2000 molecular diagnostics system.